Objectif
Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.
NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA.
Specific objectives to achieve the main goal are:
(i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric);
(ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials;
(iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging;
(iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration)
(v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations;
(vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations.
The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- engineering and technologynanotechnologynano-materials
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Appel à propositions
FP7-NMP-2013-LARGE-7
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
75724 Paris
France
Voir sur la carte
Participants (15)
75015 PARIS 15
Voir sur la carte
3584 CS Utrecht
Voir sur la carte
Participation terminée
NR7 0LB NORWICH
Voir sur la carte
50009 Zaragoza
Voir sur la carte
00 725 Warszawa
Voir sur la carte
23845 Borstel
Voir sur la carte
69007 Lyon
Voir sur la carte
SW1W 9SZ London
Voir sur la carte
28760 TRES CANTOS MADRID
Voir sur la carte
5032 GEMBLOUX
Voir sur la carte
36310 Vigo Pontevedra
Voir sur la carte
7034 Trondheim
Voir sur la carte
75015 PARIS
Voir sur la carte
EN6 1TL POTTERS BAR HERTS
Voir sur la carte
NR4 7TJ Norwich
Voir sur la carte